

ESMO 2018 Industry Satellite Symposium

Changing the natural history of breast cancer:

Where are we, and what's next in HER2-positive and triple-negative disease?

Monday 22 October, 13:00–14:30
 ICM – Room 1, Messe Munich, Munich, Germany

Agenda

Time	Topic	Speaker
13:00–13:05	Welcome and introduction	Peter Schmid, UK (chair)
13:05–13:20	Drawing closer to cure for patients with HER2-positive eBC	Javier Cortés, Spain
13:20–13:50	Shifting paradigms in mTNBC with cancer immunotherapy	Peter Schmid
13:50–14:05	Future combinations and future biomarkers in mTNBC	Rebecca Dent, Singapore
14:05–14:25	Panel discussion with Q&A	All
14:25–14:30	Summary and outlook	Peter Schmid

